Telomir Pharmaceuticals (NASDAQ: TELO) reported new research findings from The Ohio State University College of Veterinary Medicine showing that its lead compound, Telomir-Zn, produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, led by Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. These results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma, which could accelerate progress toward human therapies.
The significance of this announcement lies in its implications for cancer treatment. Osteosarcoma is a aggressive bone cancer that affects both humans and dogs, with limited treatment options and poor outcomes for metastatic disease. The fact that Telomir-Zn demonstrated comparable growth inhibition in both species at low concentrations suggests a shared biological mechanism that could be targeted therapeutically. This cross-species activity is particularly valuable because canine osteosarcoma occurs naturally and closely resembles the human disease, making it a powerful translational model. If Telomir-Zn proves effective in dogs, it could provide critical data to inform human clinical trials, potentially speeding up drug development and reducing costs.
Telomir is in discussions with The Ohio State University College of Veterinary Medicine and is assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma. This dual-purpose strategy is innovative, as it addresses an unmet need in veterinary oncology while also generating evidence that could benefit human patients. The company’s immediate focus, however, remains its triple-negative breast cancer program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared Investigational New Drug (IND) application for advanced or metastatic TNBC.
Telomir Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. Telomir-Zn is designed to modulate intracellular metal homeostasis and epigenetic regulation. The compound has already received IND clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. For more information, visit the full press release at https://nnw.fm/laeGH. The latest news and updates relating to TELO are available in the company’s newsroom at https://nnw.fm/TELO.
The broader implications of these findings extend beyond osteosarcoma. If Telomir-Zn can effectively target epigenetic and metabolic vulnerabilities common to multiple cancers, it could represent a new class of therapeutics. The fact that it works in both human and canine models suggests that its mechanism is conserved across species, which may increase confidence in its potential for human efficacy. Moreover, the use of naturally occurring canine cancers as translational models is gaining traction in the scientific community, and Telomir’s approach aligns with this trend. Successful outcomes in canine studies could provide supportive data for human trials, potentially accelerating the development timeline and improving the odds of clinical success. As Telomir advances its TNBC program, the osteosarcoma findings add another layer of promise to its pipeline, highlighting the company’s commitment to addressing difficult-to-treat cancers.
